Details of the Drug Combination

General Information of Drug Combination (ID: DCUQHXW)

Drug Combination Name
Nirogacestat Nirogacestat
Indication
Disease Entry Status REF
Triple Negative Breast Neoplasms Phase 2 [1]
Component Drugs Nirogacestat   DMUP5Z0 Nirogacestat   DMUP5Z0
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Nirogacestat
Disease Entry ICD 11 Status REF
Desmoid tumour 2F7C Approved [2]
Alzheimer disease 8A20 Phase 2 [3]
Solid tumour/cancer 2A00-2F9Z Phase 2 [4]
Nirogacestat Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Amyloid beta A4 protein (APP) TTE4KHA A4_HUMAN Inhibitor [4]
Gamma-secretase (GS) TT9W8GU APH1A_HUMAN; APH1B_HUMAN; PEN2_HUMAN; NICA_HUMAN; PSN1_HUMAN Modulator [5]
------------------------------------------------------------------------------------
Nirogacestat Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [6]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [6]
Transcription factor HES-1 (HES1) OT8P19W2 HES1_HUMAN Decreases Expression [6]
------------------------------------------------------------------------------------
Indication(s) of Nirogacestat
Disease Entry ICD 11 Status REF
Desmoid tumour 2F7C Approved [2]
Alzheimer disease 8A20 Phase 2 [3]
Solid tumour/cancer 2A00-2F9Z Phase 2 [4]
Nirogacestat Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Amyloid beta A4 protein (APP) TTE4KHA A4_HUMAN Inhibitor [4]
Gamma-secretase (GS) TT9W8GU APH1A_HUMAN; APH1B_HUMAN; PEN2_HUMAN; NICA_HUMAN; PSN1_HUMAN Modulator [5]
------------------------------------------------------------------------------------
Nirogacestat Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [6]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [6]
Transcription factor HES-1 (HES1) OT8P19W2 HES1_HUMAN Decreases Expression [6]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02299635) A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations
2 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217677
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7746).
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014.J Pharmacol Exp Ther.2010 Jul;334(1):269-77.
6 NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells. J Biol Chem. 2019 May 24;294(21):8543-8554. doi: 10.1074/jbc.RA118.006983. Epub 2019 Apr 2.